Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
MHLW Pitches Dispensing Fee Cuts for Hospitals, Pharmacies with Low Price Settlement Rates
The Ministry of Health, Labor and Welfare (MHLW) made a proposal to a key advisory council on December 25 to shed basic dispensing fees for major hospital groups and pharmacy chains with low delivery price settlement rates. The proposal, floated…
To read the full story
Related Article
- Discarded Plan to Institutionalize Key Premium Still Faces Backlash; Rough Sailing Expected before Next Reform
December 27, 2013
- Chuikyo Reps Slam Inter-Ministerial Deal to Scrap Insurance Coverage for Gargles
December 27, 2013
- Chuikyo Approves 60% Upper Limit for Evaluating Generic Drug Use at DPC Hospitals
December 27, 2013
- Trial of Cost-Effective Assessment Should Be Postponed Until FY2016 at Earliest: Expert Subcommittee
December 27, 2013
- Gist of FY2014 NHI Price Revision
December 26, 2013
- Chuikyo Approves Outline for NHI Price Reform Including New Rule for Long-Listed Drugs; Trial of Premium for New Drug Development to Continue
December 26, 2013
REGULATORY
- Japan Approves AbbVie’s Aquipta, Novo’s IcoSema, Pfizer’s Tukysa, and More
February 20, 2026
- Health Minister Signals Early March Approval for iPSC Products
February 20, 2026
- Takaichi Urges Public-Private Investment Push in Drug Discovery
February 20, 2026
- Two iPSC-Derived Products Now in Line for Conditional Approval
February 20, 2026
- PM Takaichi Keeps Cabinet Intact after Lower House Vote
February 18, 2026
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…